# XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer

> **NCT00386685** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 51 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** larotaxel (XRP9881)
- **DRUG:** trastuzumab

## Key facts

- **NCT ID:** NCT00386685
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2008-10
- **Final completion:** 2011-01
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2011-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00386685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00386685, "XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00386685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*